Aardvark Therapeutics, Inc. (AARD)
NASDAQ: AARD · Real-Time Price · USD
8.74
-1.40 (-13.81%)
At close: May 14, 2025, 4:00 PM
9.17
+0.43 (4.92%)
After-hours: May 14, 2025, 5:08 PM EDT
Aardvark Therapeutics Stock Forecast
Stock Price Forecast
According to 4 professional analysts, the 12-month price target for Aardvark Therapeutics stock ranges from a low of $21 to a high of $50. The average analyst price target of $31.5 forecasts a 260.41% increase in the stock price over the next year.
Price Target: $31.50 (+260.41%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 1, 2025.
Analyst Ratings
The average analyst rating for Aardvark Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|
| Strong Buy | 1 | 1 | 1 |
| Buy | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 |
| Total | 4 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Reiterates $21 | Buy | Reiterates | $21 | +140.27% | Apr 1, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $50 | Buy | Reiterates | $50 | +472.08% | Apr 1, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $22 → $26 | Strong Buy | Maintains | $22 → $26 | +197.48% | Mar 27, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $21 | Buy | Initiates | $21 | +140.27% | Mar 10, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates $50 | Buy | Initiates | $50 | +472.08% | Mar 10, 2025 |
Financial Forecast
Revenue This Year
n/a
from 20.49M
Revenue Next Year
n/a
EPS This Year
-2.68
from -5.15
EPS Next Year
-2.62
from -2.68
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | 3.2M | 42.0M |
| Avg | n/a | 765,000 | 20.5M |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | 5,390.2% |
| Avg | - | - | 2,578.7% |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -1.65 | -2.47 | -1.85 |
| Avg | -2.68 | -2.62 | -2.98 |
| Low | -3.49 | -2.96 | -3.92 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.